Yonsei Med J.
2003 Dec;44(6):961-967. 10.3349/ymj.2003.44.6.961.
Gastrointestinal Side Effect Profile Due to the Use of Alendronate in the Treatment of Osteoporosis
- Affiliations
-
- 1Department of Physical Medicine and Rehabilitation, Istanbul Med.Fac, Turkey. semihaki@yahoo.com
- 2Department of Physical Medicine and Rehabilitation, Cerrahpasa Med Fac, Turkey.
- 3Department of Physical Medicine and Rehabilitation, Ege Med Fac, Turkey.
- 4Department of Physical Medicine and Rehabilitation, Gulhane Mil Med Acad, Turkey.
- 5Department of Physical Medicine and Rehabilitation, Gazi Med Fac, Turkey.
- 6Department of Physical Medicine and Rehabilitation, Firat Med Fac, Turkey.
- 7Department of Physical Medicine and Rehabilitation, Trakya Med Fac, Turkey.
- 8Department of Physical Medicine and Rehabilitation, Ondokuz Mayis Med Fac, Turkey.
- 9Department of Physical Medicine and Rehabilitation, Dicle Med Fac, Turkey.
- 10Department of Physical Medicine and Rehabilitation, Selcuk Med Fac, Turkey.
- 11Department of Physical Medicine and Rehabilitation, Gaziantep Med Fac, Turkey.
- 12Department of Physical Medicine and Rehabilitation, Celal Bayar Med Fac, Turkey.
- 1370 Yil Istanbul Physical Medicine and Rehabilitation Center, Turkey.
- 14Department of Physical Medicine and Rehabilitation, Marmara Med Fac, Turkey.
- KMID: 1091034
- DOI: http://doi.org/10.3349/ymj.2003.44.6.961
Abstract
- The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, non- placebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6+/-8.6, with 51.2%in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p > 0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p < 0.05).
MeSH Terms
Cited by 1 articles
-
Effects of Adding Intravenous Pamidronate to Ongoing Menopausal Hormone Therapy in Postmenopausal Korean Women with Low Bone Mineral Density
Young-Ah Koo, Kyung-A Son, Suk-Joo Choi, Byung-Koo Yoon
J Menopausal Med. 2019;25(3):117-122. doi: 10.6118/jmm.19198.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Medical Treatment of Osteoporosis
- A Case of Alendronate - induced Gastric Ulcer
- Letter: The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Marker in Patients with Osteoporosis (Endocrinol Metab 25:305-309, 2010, Jee-Hoon Koo et al.)
- The Effects of Alendronate in Bone Metabolism of Primary Osteoporosis
- Response: The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Marker in Patients with Osteoporosis (Endocrinol Metab 25:305-309, 2010, Jee-Hoon Koo et al.)
